In this week’s Solidarity Fridays episode, David Drapkin first interviews psychiatrist, researcher, drug policy reform advocate, and Co-founder and Chief Medical Officer of Awakn Life Sciences, Dr. Ben Sessa. They discuss their frustration with the current maintenance-medication state of psychiatry and addiction treatment, drug policy in the UK, and the impressive results from the world’s first MDMA-assisted psychotherapy study to treat alcohol-use disorder. Then, in part 2, David and Kyle Buller speak with Director, CEO, and Chairman of Mydecine Innovations Group, Josh Bartch. Bartch discusses Mydecine’s compound, MYCO-001, which will be used in the first NIDA-funded study in nearly 50 years: a smoking cessation study headed up by Dr. Matthew Johnson. He discusses their app, Mindleap Health; the amazing efficacy of psilocybin on smoking cessation; microdosing; and the importance he places on reframing how psychedelics are viewed in order to inspire greater public adoption.

The post PTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh Bartch of Mydecine Innovations Group appeared first on Psychedelics Today.

Previous articleatai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai’s supply chain
Next articleMydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives